Is chimaeric antigen receptor T-cell therapy really superior to standard of care as second-line therapy for large B-cell lymphoma?

被引：1
|
作者：
Saiz, Luis Carlos [1 ]
Leache, Leire [1 ]
Gutierrez-Valencia, Marta [1 ]
Erviti, Juan [1 ]
机构：
[1] Navarre Hlth Serv, Unit Innovat & Org, Pamplona, Spain
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 200卷 / 01期
关键词：
D O I：
10.1111/bjh.18505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E6 / E7
页数：2
相关论文
共 50 条
  • [1] Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis
    Shargian, Liat
    Raanani, Pia
    Yeshurun, Moshe
    Gafter-Gvili, Anat
    Gurion, Ronit
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (05) : 838 - 846
  • [2] Second-line Treatment With CAR T-Cell Therapy for Large B-Cell Lymphoma
    Lutfi, Forat
    Patel, Ameet
    Mehta, Jasmine
    Goyal, Anmol
    Dahiya, Saurabh
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (04) : 170 - 178
  • [3] Relapsed or refractory diffuse large B-cell Lymphoma CAR-T Cell Therapy is superior to Standard Second-line Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (04) : 231 - 231
  • [4] CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis
    Shargian, Liat
    Raanani, Pia
    Yeshurun, Moshe
    Gafter-Gvili, Anat
    Gurion, Ronit
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (01) : E4 - E5
  • [5] Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis
    Kelkar, Amar H.
    Cliff, Edward R. Scheffer
    Jacobson, Caron A.
    Abel, Gregory A.
    Dijk, Stijntje W.
    Krijkamp, Eline M.
    Redd, Robert
    Zurko, Joanna C.
    Hamadani, Mehdi
    Hunink, M. G. Myriam
    Cutler, Corey
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (12) : 1625 - 1637
  • [6] Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)
    Dahiya, Saurabh
    Spiegel, Jay Y.
    Lee, Dasom
    Mohammed, Turab
    Lutfi, Forat
    Goyal, Anmol
    Hana, Caroline
    Chavez, Julio C.
    Ionescu, Filip
    Frank, Matthew J.
    Bharadwaj, Sushma
    Sandoval-Sus, Jose
    Beitinjaneh, Amer M.
    Lekakis, Lazaros J.
    McGuirk, Joseph P.
    Locke, Frederick L.
    Miklos, David B.
    Jain, Michael D.
    BLOOD, 2023, 142
  • [7] Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
    Locke, F. L.
    Miklos, D. B.
    Jacobson, C. A.
    Perales, M-A
    Kersten, M-J
    Oluwole, O. O.
    Ghobadi, A.
    Rapoport, A. P.
    McGuirk, J.
    Pagel, J. M.
    Munoz, J.
    Farooq, U.
    van Meerten, T.
    Reagan, P. M.
    Sureda, A.
    Flinn, I. W.
    Vandenberghe, P.
    Song, K. W.
    Dickinson, M.
    Minnema, M. C.
    Riedell, P. A.
    Leslie, L. A.
    Chaganti, S.
    Yang, Y.
    Filosto, S.
    Shah, J.
    Schupp, M.
    To, C.
    Cheng, P.
    Gordon, L., I
    Westin, J. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07): : 640 - 654
  • [8] Chimeric Antigen Receptor T-Cell Therapy and Imaging Applications for Large B-Cell Lymphoma
    Mulholland, Nicola
    Chandra, Julie
    Sanderson, Robin
    Kuhnl, Andrea
    RADIOLOGY, 2023, 307 (05)
  • [9] CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
    Westin, Jason
    Sehn, Laurie H.
    BLOOD, 2022, 139 (18) : 2737 - 2746
  • [10] Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
    Zhou, Wenyujing
    Chen, Weihong
    Wan, Xiaochun
    Luo, Changru
    Du, Xin
    Li, Xiaoqing
    Chen, Qian
    Gao, Ruiwen
    Zhang, Xiaohan
    Xie, Mei
    Wang, Mingjun
    FRONTIERS IN GENETICS, 2022, 12
12345